Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Natco Pharma Limited (NSE: NATCOPHARM), ISIN INE987B01026 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
NATCOPHARM last traded at ₹837.85 (+2.81%), with a 52-week range of ₹789.30 to ₹1226.10 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 49.42%, FIIs 16.99%, DIIs 5.62%, mutual funds 1.92%.
EquiSense Score (ECS): 56/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.